Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04092101 · ClinicalTrials.gov registry record · Phase 2
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
A Phase 2 study of Tobacco Use Disorder, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
- 2
- Study locations
NCT04092101 is a Phase 2 study of Tobacco Use Disorder that has completed, run by University of Vermont. The registered enrollment target is 326 participants, above the 235-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (39% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT04092101, a Phase 2 study of Tobacco Use Disorder, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prevalence of smoking among individuals with opioid use disorder (OUD) is six-fold that of the general US adult population. The mortality rate of opioid-dependent smokers is four times that of opioid-dependent nonsmokers, and their response to smoking cessation interventions is notoriously poor. A national policy of reducing the nicotine content of cigarettes has the potential to be an effective method of reducing tobacco use prevalence, dependence, and related adverse health outcomes. Controlled trials in the general smoker population have demonstrated that switching smokers to low nicotine content cigarettes results in reductions in cigarettes per day (CPD), dependence and tobacco toxicant exposure, with few adverse consequences. The investigators believe that the impact of reduced nicotine standards on use of combusted cigarettes in this population will be moderated considerably by other tobacco market conditions including (1) availability of alternative sources of non-combusted nicotine, and (2) whether these alternatives are available under conditions that optimize their appeal. The investigators hypothesize the same for other vulnerable populations as well, but achieving significant reductions in use of combusted cigarettes in smokers with OUD seems especially unlikely in the absence of readily available and appealing alternative sources of non-combusted nicotine. The goal of the proposed trial is to experimentally model whether increased availability and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) will enhance the effectiveness of a reduced nicotine standard for cigarettes in smokers with OUD. Additionally, the investigators will test whether allowing participants to personalize the favor of the e-liquid alters any moderating effects their availability may have on tobacco cigarette smoking. Daily smokers who are receiving methadone or buprenorphine treatment will be recruited at University of Vermont and Johns Hopkins Universit
Conditions Studied
Interventions
- OTHER Cigarettes with varying nicotine content
- OTHER E-Cigarettes
Study Locations (2)
Maryland
- Johns Hopkins University - Baltimore
Vermont
- Shirley Plucinski - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2020-10-18 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04092101
The ClinicalTrials.gov registry entry for NCT04092101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 235-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (39% higher). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cigarettes with varying nicotine content is the first listed.
NCT04092101 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Vermont.
Frequently Asked Questions
What is clinical trial NCT04092101 about?
NCT04092101 is a clinical study titled "Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder". Prevalence of smoking among individuals with opioid use disorder (OUD) is six-fold that of the general US adult population. The mortality rate of opioid-dependent smokers is four times that of opioid-dependent nonsmokers, and their response to smoking cessation interventions is notoriously poor. A n...
What is the current status of trial NCT04092101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2020-10-18. Estimated completion is 2023-11-27.
What conditions does trial NCT04092101 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT04092101?
The interventions under investigation include: Cigarettes with varying nicotine content (OTHER), E-Cigarettes (OTHER).
Who is sponsoring clinical trial NCT04092101?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04092101 being conducted?
This trial has 2 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.